Neal Shore, MD, FACS, highlights the efficacy data from the EMBARK study, toxicities observed with enzalutamide alone or in combination with a LHRH agonist, and the significance of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.
The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.